Severna Park, MD, United States of America

Mark F Pittenger

USPTO Granted Patents = 23 

 

 

Average Co-Inventor Count = 2.8

ph-index = 16

Forward Citations = 1,190(Granted Patents)


Company Filing History:


Years Active: 1998-2022

Loading Chart...
Loading Chart...
Loading Chart...
23 patents (USPTO):Explore Patents

Title: Mark F. Pittenger: Pioneer in Regenerative Medicine

Introduction

Mark F. Pittenger, based in Severna Park, MD, has made a remarkable impact in the field of regenerative medicine with an impressive portfolio of 23 patents. His innovative research primarily focuses on mesenchymal stem cells and their applications in wound healing.

Latest Patents

Among his latest contributions to the field are patents centered around the use of mesenchymal stem cells. These patents detail compositions and methods for promoting wound healing in humans by administering mesenchymal stem cells in effective amounts. This work is vital for advancing treatments for various injuries and enhancing recovery processes.

Career Highlights

Throughout his career, Mark has been associated with notable companies, including Osiris Therapeutics, Inc. and Mesoblast International Sarl. His work in these organizations has allowed him to lead and contribute to groundbreaking research aimed at improving health outcomes through innovative medical solutions.

Collaborations

In his endeavors, Mark has collaborated with esteemed colleagues such as Stephen L. Gordon and Alastair Morgan Mackay. These partnerships have fostered a collaborative environment that has nurtured innovative approaches and yielded significant advancements in regenerative medicine.

Conclusion

Mark F. Pittenger exemplifies the spirit of innovation and dedication in the field of regenerative medicine. His extensive patent portfolio and collaborative efforts signify his commitment to enhancing medical treatments and improving patient care through the application of mesenchymal stem cells.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…